Anticoagulation Bridging: Indications, Contra‑indications, and Management

High‑Risk Patients Requiring Bridging

• Mechanical mitral valve replacement mandates peri‑operative bridging regardless of other factors because it carries the highest thrombotic risk (American College of Cardiology) 1
• Older‑generation mechanical aortic valves (ball‑cage or tilting‑disk designs) require bridging due to their elevated embolic potential (American College of Cardiology) 1
• Modern bileaflet mechanical aortic valves need bridging only when an additional thromboembolic risk factor is present (e.g., prior stroke/TIA, atrial fibrillation, left‑ventricular dysfunction, hypercoagulable state) (American College of Cardiology) 1
• Modern bileaflet mechanical aortic valves without additional risk factors do not require bridging when warfarin interruption is brief (American College of Cardiology) 1
• Recent arterial thromboembolism (stroke or TIA within the prior 3 months) in patients with atrial fibrillation warrants bridging (American Heart Association/American Stroke Association) 2
• Recent venous thromboembolism (deep‑vein thrombosis or pulmonary embolism within the prior 3 months) warrants bridging (American Heart Association/American Stroke Association) 2
• Very high CHA₂DS₂‑VASc scores (≥6) or CHADS₂ scores of 5–6 in atrial‑fibrillation patients may justify bridging, although benefit is evident only at these extreme scores (American Heart Association/American Stroke Association) 2
• Active rheumatic mitral stenosis or other rheumatic valve disease with atrial fibrillation requires bridging (American Heart Association/American Stroke Association) 2

Patients Who Should Not Receive Bridging

• The majority of atrial‑fibrillation patients should not be bridged because bridging increases major bleeding without reducing thromboembolic events (American College of Cardiology) 1
• Patients with CHA₂DS₂‑VASc scores below 6 derive no benefit from bridging and experience net harm from bleeding (American College of Cardiology) 1
• Bioprosthetic‑valve patients on anticoagulation for atrial fibrillation are managed according to CHA₂DS₂‑VASc score, not valve type; bridging is generally unnecessary unless the score is ≥6 (American College of Cardiology) 1

Practical Bridging Protocol When Indicated

Pre‑operative Management

• Discontinue warfarin 3–4 days before surgery to achieve an INR < 1.5 (American College of Cardiology) 1
• Initiate therapeutic‑dose low‑molecular‑weight heparin (LMWH) or unfractionated heparin when INR falls below 2.0–2.5, typically 36–48 hours before the procedure (American College of Cardiology) 1
• Stop LMWH 12 hours before surgery (or unfractionated heparin 4–6 hours prior) to minimize intra‑operative bleeding (American College of Cardiology) 1

Post‑operative Management

• Resume warfarin at the usual therapeutic dose 12–24 hours after surgery once hemostasis is confirmed (American College of Cardiology) 1
• Restart therapeutic‑dose LMWH or unfractionated heparin 24 hours post‑operatively if the bleeding risk is acceptable (American College of Cardiology) 1
• Continue bridging until the INR returns to the therapeutic range (≥2.0) (American College of Cardiology) 1

Bleeding Risk Assessment

• Bridging increases major bleeding risk approximately 3–5‑fold compared with no bridging (American College of Cardiology) 1
• A HAS‑BLED score > 2 signals bleeding risk that may outweigh any thrombotic benefit, even in high‑risk patients (American College of Cardiology) 1

Procedure‑Specific Recommendations

• Do not interrupt anticoagulation for low‑bleeding‑risk procedures (e.g., dental cleaning, cataract surgery, minor dermatologic interventions) because local measures adequately control bleeding (American College of Cardiology) 1

Perioperative Anticoagulation Management

General Principles

• The American College of Cardiology recommends stopping anticoagulation therapy 2-4 days before invasive procedures when bleeding risk is significant, and restarting 12-24 hours after surgery when hemostasis is adequate 3
• The decision to stop anticoagulation must balance the risk of thromboembolism against the risk of bleeding during the procedure, according to the American Heart Association 4, 3
• Thromboembolism risk factors include mechanical heart valves, atrial fibrillation with additional risk factors, and recent venous thromboembolism, as stated by the American College of Cardiology 3
• Procedures with low bleeding risk may not require anticoagulation interruption, as recommended by the American Heart Association and the American College of Chest Physicians 4, 5

Low Bleeding Risk Procedures

• The American Heart Association recommends continuing anticoagulation for dental procedures, such as extractions, cleaning, and caries treatment 4
• Cataract or glaucoma surgery and minor skin procedures are also considered low bleeding risk and may not require anticoagulation interruption, according to the American Heart Association and the American College of Cardiology 4, 3

High Bleeding Risk Procedures

• For vitamin K antagonists like warfarin, the American College of Chest Physicians recommends stopping 5 days before surgery to allow INR to fall below 1.5 5
• The American College of Cardiology suggests resuming anticoagulation 12-24 hours after surgery when hemostasis is achieved 3
• For direct oral anticoagulants, the European Society of Cardiology recommends stopping 48-72 hours before high bleeding risk procedures, considering renal function and specific agent 6

Bridging Anticoagulation

• The American College of Cardiology recommends bridging anticoagulation for mechanical mitral valve replacement, older-generation mechanical aortic valve, and mechanical aortic valve with additional risk factors 3
• The American Heart Association suggests bridging for recent venous thromboembolism, especially within 3 months 5
• The American College of Chest Physicians recommends stopping warfarin 5 days before procedure and starting therapeutic-dose LMWH or UFH when INR falls below therapeutic range 5, 4

Special Situations

• In emergency surgery, the American College of Cardiology recommends administering 4-factor prothrombin complex concentrate for patients on VKAs, and considering low-dose vitamin K 3
• The American Heart Association suggests avoiding high-dose vitamin K to prevent rebound hypercoagulability 4

Duration of Anticoagulation Therapy

• For venous thromboembolism, the American College of Chest Physicians recommends treating for 3 months, then stopping for provoked VTE, and minimum 3 months with reassessment for extended therapy for unprovoked proximal DVT or PE 7
• The American Society of Hematology recommends indefinite anticoagulation for recurrent unprovoked VTE with low bleeding risk 7, 8
• For cancer-associated thrombosis, extended anticoagulation is recommended while cancer is active, according to the American Society of Hematology 9

Common Pitfalls to Avoid

• The American Heart Association and the American College of Cardiology warn against stopping anticoagulation for low bleeding risk procedures unnecessarily, which increases thrombotic risk 4, 3
• The American Heart Association recommends avoiding high-dose vitamin K for warfarin reversal to prevent prolonged resistance to re-anticoagulation 4
• The American College of Cardiology suggests restarting anticoagulation promptly after surgery when hemostasis is adequate 3
• The European Society of Cardiology recommends considering patient-specific factors like renal function when managing DOACs 6